



**Alpha Cognition Inc.**  
**Nasdaq: ACOG**  
1452 Hughe Road,  
Ste.200  
Grapevine, TX 76051  
[www.alphacognition.com](http://www.alphacognition.com)  
[info@alphacognition.com](mailto:info@alphacognition.com)

## Alpha Cognition Inc. to Participate in Three Upcoming Investor Conferences

VANCOUVER, B.C., and Grapevine, TX – April 27, 2026 – **Alpha Cognition, Inc. (ACOG: NASDAQ)** (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that Michael McFadden, Chief Executive Officer, will participate in three investor conferences in May.

### Event details are as follows:

#### **Market Movers Investor Summit**

Format: Presentation and 1x1 meetings

Date/Time: Tuesday, May 5 at 2:40 p.m. ET

#### **H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq**

Format: Fireside Chat and 1x1 meetings

Date/Time: Tuesday, May 19 at 4:30 p.m. ET

#### **Craig Hallum’s 23<sup>rd</sup> Annual Institutional Investor Conference**

Format: 1x1 meetings

Date: May 28, 2026

A live webcast of select presentations will be accessible in the Events & Presentations section of the Company’s investor relations website and archived for replay following the events.

### **About Alpha Cognition Inc.**

Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options.

ZUNVEYL is a patented drug approved as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ZUNVEYL’s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI.

### **For further information:**

#### **Investor Relations**

LifeSci Advisors, PJ Kelleher

[pkelleher@lifesciadvisors.com](mailto:pkelleher@lifesciadvisors.com)



## Forward-looking Statements

This news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward-looking statement that reflects the Company's current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Such statements include but are not limited to statements regarding the future success of the commercialization of ZUNVEYL, statement regarding the timing and potential outcomes of the Company's ongoing clinical and preclinical studies, statements regarding future presentations, statements regarding potential product approvals and other statements regarding the future anticipated operations of the Company. In some cases, you can identify forward-looking statements by the words "may," "might," "will," "could," "would," "should," "expect," "intend," "plan," "objective," "anticipate," "believe," "estimate," "predict," "project," "potential," "target," "seek," "contemplate," "continue" and "ongoing," or the negative of these terms, or other comparable terminology intended to identify statements about the future. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot ensure that the actual results will be consistent with these forward-looking statements. These forward-looking statements are subject to certain risks, including risks regarding our ability to raise sufficient capital to implement our plans to continue to commercialize ZUNVEYL, risks regarding the efficacy and tolerability of ZUNVEYL, risks related to ongoing regulatory oversight on the safety of ZUNVEYL, risk related to market adoption of ZUNVEYL, risks related to the Company's intellectual property in relation to ZUNVEYL, risks related to the commercial manufacturing, distribution, marketing and sale of ZUNVEYL, risks related to product liability, risks related to our ongoing clinical trials and other risks as described in the Company's filings with Canadian securities regulatory authorities and available at [www.sedar.com](http://www.sedar.com) and the Company's filings with the United States Securities and Exchange Commission (the "SEC"), including those risk factors under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the SEC on March 31, 2025 and the Company's other filings with the SEC available at [www.sec.gov](http://www.sec.gov). These forward-looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward-looking statements for any reason, even if new information becomes available in the future, except as required by law.